High-dose versus conventional-dose chemotherapy asfirst-salvage treatment in patients with non-seminomatousgerm-cell tumors: a matched-pair analysis

Abstract

BackgroundThe purpose of this study was to compare high-dose chemotherapy (HDCT) with conventional-dose chemotherapy (CDCT) as first-salvage treatment in patients with relapsed or refractory non-seminomatous germ-cell tumors (NSGCT). Patients and methodsOne hundred and ninety-three patients with relapsed or refractory NSGCT, between 1981 and 1995, were identified from two large databases. In 74 of these, intensification of first-salvage treatment by HDCT was planned. Patients were matched based on primary tumor location, response to first-line treatment, duration of this response and serum levels of the tumor markers, human chorionic gonadotrophin (HCG) and α-fetoprotein (AFP). Multivariate analyses were performed using event-free survival and overall survival as primary endpoints. ResultsFull matches on all five factors were found for 38 pairs of patients; for a further 17 pairs, matches on at least four factors could be identified. Hazard ratios in favor of HDCT were obtained between 0.72 and 0.84 [confidence interval (CI) 0.59–1.01] for event-free survival and between 0.77 and 0.83 (CI 0.60–0.99) for overall survival, depending on the type of analysis. ConclusionsThe current analysis suggests a benefit from HDCT, with an estimated absolute improvement in event-free survival of between 6 and 12% and in overall survival of between 9 and 11% at 2 years. This benefit is lower than expected from previous phase I/II studies.